William Waldrip
Family Medicine · Batesville, ARNPI 1427044999
Payments from drug & device makers
Across 87 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$484
- Pfizer$180
- AstraZeneca$150
- Novo Nordisk$117
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
- Medtronic$81
- plus $331 from 12 others
What the payments were for
- Food & beverage$1,429100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 32 | $484 |
| Pfizer | 11 | $180 |
| AstraZeneca | 11 | $150 |
| Novo Nordisk | 7 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $86 |
| Medtronic | 1 | $81 |
| Johnson & Johnson | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Genentech USA, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $28 |
| Merck | 2 | $27 |
| Amarin Pharma, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $21 |
| Novartis | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| GSK | 1 | $11 |
How this compares
$1,429 in reported general payments places this provider in the 65th percentile of 1,347 family medicine providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 52 | $42,711 |
| XareltoRivaroxaban | 20 | $21,559 |
| OzempicSemaglutide | 21 | $19,768 |
| JanuviaSitagliptin Phosphate | 22 | $17,021 |
| TrulicityDulaglutide | 12 | $16,515 |
| JardianceEmpagliflozin | 15 | $14,589 |
| MounjaroTirzepatide | 13 | $13,624 |
| MyrbetriqMirabegron | 14 | $9,206 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,124 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $8,896 |
| FarxigaDapagliflozin Propanediol | 12 | $7,878 |
| Atorvastatin Calcium | 266 | $2,279 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,953 |
| Levothyroxine Sodium | 140 | $1,502 |
| Metoprolol Succinate | 76 | $1,382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $180 | $42,71152 claims |
| Johnson & JohnsonXarelto | $69 | $21,55920 claims |
| Novo NordiskOzempic | $117 | $19,76821 claims |
| MerckJanuvia | $27 | $17,02122 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $9,20614 claims |
| GSKTrelegy Ellipta | $11 | $9,12411 claims |
| AstraZenecaFarxiga | $150 | $7,87812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Batesville
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.